Effect of metformin and adriamycin on transplantable tumor model.
Adriamycin is a cytotoxic anthracycline antibiotic used in treatment of many types of cancer. Metformin is antidiabetic drug and is under investigation for treatment of cancer. The aim of this work was to study the effect of each of adriamycin and metformin alone and in combination on solid Ehrlich carcinoma (SEC) in mice. Eighty BALB/C mice were divided into four equal groups: SEC group, SEC+adriamycin, SEC+metformin, SEC+adriamycin+metformin. Tumor volume, survival rate, tissue catalase, tissue reduced glutathione, tissue malondialdehyde, tissue sphingosine kinase 1 activity, tissue caspase 3 activity and tissue tumor necrosis factor alpha were determined. A part of the tumor was examined for histopathological and immunohistochemical study. Adriamycin or metformin alone or in combination induced significant increase in the survival rate, tissue catalase, reduced glutathione and tissue caspase 3 activity with significant decrease in tumor volume, tissue malondialdehyde, tissue sphingosine kinase 1 activity and tumor necrosis factor alpha and alleviated the histopathological changes with significant increase in Trp53 expression and apoptotic index compared to SEC group. In conclusion, the combination of adriamycin and metformin had a better effect than each of these drugs alone against transplantable tumor model in mice.
Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia; Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt. Electronic address: drakabel@gmail.com.
Ahmed M
AM
Kabel
Division of Biochemistry, Pharmacology and Toxicology Department, College of Pharmacy, Taif University, Taif, Saudi Arabia; Chemistry Department, Faculty of Science, Benha University, Benha, Egypt.
Mohamed S
MS
Omar
Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Mohamed F
MF
Balaha
Department of Physiology, Faculty of Medicine, Kafrelsheikh University, Egypt.
Hany M
HM
Borg
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000494:pharmacology*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008315:Malondialdehyde / Q000378:metabolism; D008687:Metformin / Q000494:pharmacology*; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; D007004:Hypoglycemic Agents; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D004317:Doxorubicin; D008687:Metformin
Adriamycin; Metformin; Mice; Transplantable tumor